The fair value of requested stock should be $99.54
* Note: Prices are in Million (M) USD.
These criteria used Company’s Cash, EBITDA and Debt balance to determines its fair value:
Cash : $7,020 M
Debt : $747 M
EBITDA : $-3,760 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Biotechnology
Based on industry, 5 points assigned.
This criteria used Company’s Price To Earning (P/E) Ratio to determines its fair value:
Error: EPS must be a positive number.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $2,521 M
Average Revenue: $7,585 M
Free Cash Flow to Revenue : 33 %
Since Free Cash Flow (FCF) to Revenue percentage is greater than 25, 5 points assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2023-12-31): $6,775 M
Revenue 4 Years Ago (2019-12-31): $60 M
Revenue Growth: 2238%
Since Revenue Growth is greater than 20, 5 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2023-12-31): $382 M
Share Count 5 Years Ago (2019-12-31): $337 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Error: Invalid Earnings Per Share value.Using default values for calculation.
Based on default values, 1 points assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: -0%
Since Average ROE is negative, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $27
52-Week Low: $29
Threshold Price (15% Above 52-Week Low): $34
Since Current price is within 15% threshold, 5 points assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $12,032 M
Since Market Cap is between 10B - 100B, 2 points assigned.
% Exposure to Total Portfolio
Based on the calculated score, we recommend do not exceed 3% exposure of Total Portfolio.
Value-Trade has assigned 25 points to above Moderna Inc (MRNA) stock.
Can't calculate fair value because earning per share is negative.Twenty Years Avg PE 5, Fair Value PE 25, Industry Based PE is 20 and Growth based PE is 40. Based on these all values average assigned is 22.50.
Value-Trades has assined P/E value 22.50. Since current year earning per share is $-8.97.
The fair value of Moderna Inc (MRNA) stock should be (22.50 x $-8.97) = $-201.83
Join Discussion Group